similarities with vasospastic individuals, in contrast to controls as shown in Figure 1 [3] . Although DNA damage in the vasospastic non-glaucomatous group is not found to be significantly increased versus healthy controls, DNA from vasospastic individuals showed highly groupspecific comet-patterns with the degree of damage intermediate between healthy controls and glaucoma patients.
Conclusions and outlook
These findings indicate "comet assay" profiling of DNAdamage in CL as a potentially powerful tool for the non-invasive early/predictive molecular diagnostics of glaucoma disease in vasospastic individuals. Furthermore, unrepaired DNA-damage in vasospastic individuals can lead to several pathologies different from glaucomatous optic nerve degeneration. This predisposition should be thoroughly investigated and the specificity of "Comet Assay"-patterns of vasospastic individuals should be validated comparing with patterns of other degenerative and non-degenerative pathologies. Thus, "Comet Assay"-analysis as a suitable tool for biomarkers has also been suggested for another neurodegenerative disorder -Alzheimer's disease [4] . "Comet Assay"-analysis reveals enhanced DNA damage in both high-and normaltension glaucoma [3] . Whether the level of DNA-damage correlates with disease severity, or not remains currently unclear. Further studies should also evaluate, whether a significant increase in DNA damage of leukocytes of glaucoma patients is caused by either disease specific stress factors, such as local ischemic/reperfusion events, and/or decreased capacity of DNA-repair machinery. There is some evidence for both eventualities: simultaneous up-regulation of p53 (stress regulated gene) and down-regulation of XPGC (essential member of DNA-repair machinery) have been demonstrated ex vivo in CL of glaucoma patients [5] and represent potential molecular blood markers for the disease.
Recommendations
A potential predisposition of vasospastic individuals to related pathologies should be thoroughly examined. This examination requires innovative strategies to cover following aspects:
• identification of possible similarities as well as dissimilarities in molecular pathways between healthy vasospastic individuals and potential related pathologies developed later in life
• specificity for predictive diagnostics of glaucoma pathology in predisposed vasospastic individuals should Figure 1 Ex vivo "Comet Assay"-analysis of DNA damage in circulating leukocytes of glaucoma patients and non-glaucomatous vasospastic individuals versus healthy controls [3] . Figures A-D give examples of images typical for A. control group, B. group of vasospastic individuals, C. group of normal-tension glaucoma patients, and D. group of high-tension glaucoma patients. Comet-patterns typical for healthy controls (A) show that chromosomal DNA is localised mainly to heads of comets (intact DNA). In contrast, images B, C, and D demonstrate clearly damaged DNA (visible comet-tails and diffuse comet-heads).
be strictly validated against several control groups including other neuro/degenerative diseases
• selection of molecular targets should be performed for vasospastic individuals in favour of non-invasive (blood test) diagnostic approaches followed by personalised treatment towards individual predisposition to single pathologies. 
